Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Annji Pharmaceutical CoROCO:7754 +5.90%18 Debt-to-Equity is 0.11 as of Jun. 2026, which is 38% above its 10-year median of 0.08. GuruFocus rates ROCO:7754 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 964 Biotechnology companies, Annji Pharmaceutical Co ranks better than 57.47% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Annji Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:
ROCO:7754'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.08 Max: 0.15
Current: 0.11
During the past 5 years, the highest Debt-to-Equity Ratio of Annji Pharmaceutical Co was 0.15. The lowest was 0.00. And the median was 0.08.
ROCO:7754's Debt-to-Equity is ranked better than 57.47% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs ROCO:7754: 0.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Annji Pharmaceutical Co Debt-to-Equity Related Terms
Annji Pharmaceutical Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7754 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Annji Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annji Pharmaceutical Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Annji Pharmaceutical Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annji Pharmaceutical Co (ROCO:7754) has a Debt-to-Equity of 0.11 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Annji Pharmaceutical Co and its competitors. This is 38% above median its historical median of 0.08. According to the industry distribution chart, Annji Pharmaceutical Co ranks #410 out of 964 companies in the Biotechnology industry, placing it in the top 42.5%.
Is Annji Pharmaceutical Co's Debt-to-Equity too high?
Annji Pharmaceutical Co's current Debt-to-Equity of 0.11 is 38% above median its 10-year median of 0.08. The Biotechnology industry median Debt-to-Equity is 0.16. Annji Pharmaceutical Co's value of 0.11 is 29% below this industry median. Based on the distribution chart, Annji Pharmaceutical Co ranks #410 out of 964 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Annji Pharmaceutical Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annji Pharmaceutical Co ranks #410 out of 964 companies for Debt-to-Equity. This puts Annji Pharmaceutical Co in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Annji Pharmaceutical Co's value of 0.11 is 29% below this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 0.16, Annji Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annji Pharmaceutical Co's current Debt-to-Equity of 0.11 is 29% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Annji Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annji Pharmaceutical Co's current Debt-to-Equity is 0.11, which is 38% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current Debt-to-Equity of 0.11. The current Debt-to-Equity is 0.11, which is 38% above median its 10-year median of 0.08 and 29% below the Biotechnology industry median of 0.16. Annji Pharmaceutical Co's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current Debt-to-Equity is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
18GF Score
Get the complete analysis for ROCO:7754
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7754 has been successfully added to your 
